Molecular Subtyping and Clinical Outcomes in Colorectal Cancer

Colorectal cancer exhibits substantial heterogeneity at molecular, cellular and microenvironmental levels. Advances in transcriptomic and pathway analyses have given rise to robust subtyping frameworks—most notably consensus molecular subtypes (CMS), cancer‐cell intrinsic subtypes (CRIS) and more recently pathway‐derived subtypes (PDS). These classification systems integrate gene expression profiles, stromal and immune signatures, and biological activation states to stratify tumours into groups with distinct prognostic trajectories and therapeutic vulnerabilities. Molecular subtype assignment informs clinical decision-making by predicting response to chemotherapy, targeted agents and immunotherapy, guiding patient selection for stratified trials. Implementation of rigorous subtyping in routine practice promises to refine prognostic models, reveal novel drug targets and improve global management of colorectal cancer.

Research from Nature Portfolio

Recent studies have applied pathway-level analysis to refine CRC stratification beyond conventional gene-level signatures. One investigation defined three pathway-derived subtypes—PDS1, PDS2 and PDS3—characterised by stem cell marker expression, tumour microenvironment composition and proliferative states. Notably, the slow-cycling PDS3 subset, previously obscured within CMS2, associates with the worst prognosis in locally advanced disease, underscoring the need for classifiers that capture subtle biological states. Another study tracked platinum-based drug distribution after oxaliplatin-based chemotherapy and revealed persistent drug retention in cancer-associated fibroblasts. This accumulation amplifies TGF-β activity and upregulates stromal markers such as periostin in CMS4 tumours, fostering resistance and aggressive behaviour. Identification of stromal drug reservoirs provides a framework for targeting the microenvironment to overcome chemoresistance.

Molecular Subtyping and Clinical Outcomes in Colorectal Cancer publication trend

The graph below shows the total number of articles in molecular subtyping and clinical outcomes in colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Consensus molecular subtypes (CMS): A gene expression-based classification dividing colorectal cancers into four major subtypes with distinct biology and clinical outcomes.

Pathway-derived subtypes (PDS): Molecular classes identified by pathway activation and gene ontology analyses that capture tumour phenotypes not detected by gene-level classifiers.

Cancer-associated fibroblasts (CAFs): Stromal cells within the tumour microenvironment that interact with cancer cells and influence progression and drug response.

Multi-label classification: An analytical approach allowing simultaneous assignment of multiple subtype labels to a single tumour sample to reflect intratumour heterogeneity.

p21-activated kinase 2 (PAK2): A serine/threonine kinase regulating cytoskeletal dynamics and focal adhesion, identified as essential for growth and metastasis of mesenchymal colorectal cancer.

References

1. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer. Nature Genetics (2024).
2. Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Nature Communications (2023).
3. Multi-label transcriptional classification of colorectal cancer reflects tumor cell population heterogeneity. Genome Medicine (2023).
4. Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer. Journal of Experimental & Clinical Cancer Research (2023).